Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

34
Market Update: PSU banks push Nifty higher led by BoB, PNB; RIL, GAIL up 1-3%, PC Jeweller zooms 38%

2018-05-07 moneycontrol
The Indian equity market extended gains and was trading on a positive note on Monday afternoon with the Nifty gaining 79 points and was trading at a shade below 10,700 at 10,697 while the Sensex was up 248 points or 0.71 percent.
500325 532714 539437 532483 534816 GAILF CLNDY RLNIY SBAZ TVSMOTOR AXB 501425 APOLLOTYRE YYBKY AYRQY BBTC CNRYY AXBA GAILY 534809 TCS HINDPETRO PCJEWELLER 500104 CANBK COALINDIA BHRYY 533150 RELIANCE 533273 TTNQY 533278 532215 532343 532540 IDFCBANK 532461 AXISBANK RIGD INFRATEL KEC YESBANK HINDALCO 500877 IBN 532648 AXBKY HNDNF ICICIBANK OBZIY GODREJPROP OBEROIRLTY PNJZY 532174 501455 PNB GREAVESCOT 500440

39
Market Update: Axis Bank, Hindalco up 2-3% while Lupin sheds 3%; Jubilant Food hits new 52-week high

2018-05-07 moneycontrol
The Indian equity market extended loses was trading on a negative note on Monday afternoon with the Nifty gaining 36 points was trading at 10,654 while the Sensex was up 96 points or 0.28 percent.
531500 539437 532960 532483 EICHERMOT CLNDY SBAZ RAJESHEXPO AXB 501425 BBTC CNRYY AXBA TATASTEEL TATLY 534809 TCS HINDPETRO PCJEWELLER 500104 CANBK COALINDIA 533150 533273 TTNQY 533278 IDBLZ 532215 505200 500470 532540 IDFCBANK 532461 AXISBANK ECQRY HINDALCO IBVENTURES IBN AXBKY HNDNF ICICIBANK OBZIY GODREJPROP TTST OBEROIRLTY PNJZY 532174 PNB 500440

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...